ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Typically, asciminib (ABL001) is a potent and selective allosteric Abl1 inhibitor, which binds to the myristoyl pocket of Abl1 and induces the formation of an inactive kinase conformation.259 Phase I clinical trials are being conducted to evaluate the efficacy and safety of this drug alone or in combination with dasatinib and prednisone in patients with CML or BCR-ABL-positive B-cell ALL (NCT02081378, NCT03595917).